Drug Policy - what Is it in Poland and UE

• Autorzy: Wojciech Giermaziak
• Języki publikacji: EN

Abstrakty

EN

Demographic situation - growth population of people advanced in years, greater detestability of illnesses connected with better diagnostic methods and partial covering of the costs of medicines from the public funds what causes the growth of financial expenditure for the protection of health. Considering the payment possibility of the public payer, which is obligated to finance health care services, decisions to be taken in this field must be based on clear specific requirements and defined and verified information. A proper state body which is authorized to create the structured and conscious drug policy should take planned operations aiming at rationalization of budgetary expenditure and furthermore the supply of safe, effective and cheap drugs to patients.(original abstract)

Słowa kluczowe

EN

Medications; Health care protection; Financing of health protection

PL

Leki; Ochrona zdrowia; Finansowanie ochrony zdrowia

• Czasopismo: Journal of Health Policy and Outcomes Research
• Rocznik: 2012
• Numer: nr 1
• Strony: 7--11

Twórcy

autor

Wojciech Giermaziak

• Departament of Drug Policy and Pharmacy, Ministry of Health

Bibliografia

• Bochenek T., Kozierkiewicz A. Ceny i refundacja leków . Termedia, Poznań 2009
• Annemans L. Health economics for non-economists. An introduction to the concepts, methods and pitfalls of health economic evaluation
• OECD, Pharmaceuticals Pricing Policies In Global Market, 2008
• Łanda K. Pricing - ceny leków refundowanych, negocjacje i podział ryzyka praca zbiorowa; Kraków 2009
• Innovative Medicine. Available from: http://imi.europa.eu/index_en.html;
• Polski Związek Pracodawców Przemysłu Farmaceutycznego Pigułka; nr 30, grudzień 2009
• Innovative Medicine. Available from: http://imi.europa.eu/index_en.html;
• Pollack A. Pricing pills by the results. 2007
• EFPIA. The pharmaceutical in figures, 2009; Innovative Medicine. Available from: http://imi.europa.eu/index_en.html;
• Garattini L. et. al. Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis. Health Policy, 2007

Identyfikatory

DOI

10.7365/JHPOR.2012.1.2